Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Howard Haronian

Cardiovascular Disease Charlotte, NC Medical Doctor

NPI 1548258635 CMS profile 69192

125 Queens Rd Ste 200, Charlotte, NC 28204

Open in the dashboard

General payments

$39,235

269 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$45,979 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Howard Haronian of Charlotte, NC is reported in the CMS Open Payments database as having received $39,235 across 269 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $45,979 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,132 29
2024 General $14,405 68
2023 General $12,113 44
2022 General $8,521 69
2021 General $892 13
2020 General $436 15
2019 General $735 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Howard Haronian
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Howard Haronian were reported at $2,132. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Howard Haronian Cardiovascular Disease median Middle half National median
2019 $735 $450 $127–$1,392 $163
2020 $436 $242 $77–$751 $114
2021 $892 $335 $101–$1,037 $132
2022 $8,521 $395 $121–$1,211 $149
2023 $12,113 $443 $136–$1,283 $160
2024 $14,405 $450 $136–$1,323 $164
2025 $2,132 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $31,628 127 payments
  2. Amgen Inc. $2,244 29 payments
  3. Medtronic, Inc. $1,061 17 payments
  4. Janssen Pharmaceuticals, Inc $917 12 payments
  5. Philips Electronics North America Corporation $530 8 payments
  6. Impulse Dynamics (USA) Inc. $485 5 payments
  7. Siemens Medical Solutions USA, Inc. $311 3 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $300 10 payments
  9. AstraZeneca Pharmaceuticals LP $226 8 payments
  10. Boston Scientific Corporation $224 5 payments
  11. Other $1,309 45 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $21,875 23 payments
  2. Food and Beverage $13,049 219 payments
  3. Travel and Lodging $4,311 27 payments
Products named General payments · program years 2019–2025
  1. CARDIOMEMS Heart failure $29,716 102 payments
  2. Repatha Cardiology $1,474 18 payments
  3. XARELTO $917 12 payments
  4. CardioMEMS HF System Heart failure $560 5 payments
  5. CardioMEMS HF System Cardiac Arrhythmias and Heart Failure $439 8 payments
  6. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $308 2 payments
  7. JARDIANCE $300 10 payments
  8. Optimizer $297 3 payments
  9. CARDIOMEMS Structural Heart $294 6 payments
  10. REPATHA Cardiovascular $193 3 payments
  11. Other $3,879 94 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

1,125

Median for Cardiology: 2,533

Drug cost

$185,919

Median for Cardiology: $485,213

Branded share of claims

21.1%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 102 $94,221
Entresto Sacubitril/Valsartan Brand 34 $42,712
Xarelto Rivaroxaban Brand 24 $23,897
Repatha Sureclick Evolocumab Brand 17 $11,078
Metoprolol Succinate Generic 168 $2,689
Atorvastatin Calcium Generic 136 $1,309
Olmesartan Medoxomil Generic 51 $1,213
Nebivolol Hcl Generic 16 $1,009
Olmesartan-Hydrochlorothiazide Olmesartan/Hydrochlorothiazide Brand 33 $920
Bumetanide Generic 13 $760

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$20,665

Medicare's payments for the services billed

Medicare patients

142

Average age 80

Services billed

428

65 women, 77 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 47%
Arthritis 46%
Ischemic heart disease 42%
Heart failure 40%
Diabetes 38%
Chronic kidney disease 32%
Depression 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $428
$428 24 —
Repatha
  • Amgen Inc. $357
$357 17 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $37
$37 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $22
$22 34 —
VERQUVO
  • Merck Sharp & Dohme Corporation $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

269 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record